News Briefs Cancer drug developer Rgenix nets $33 mln Series B Iris Dorbian - 15 June 2016 Share A- A+ 100% Create an account to continue reading Gain instant access to our expert editorial analysis and in-depth insight. Register for free Already have an account? Sign in